Floatz logo

Maplirpacept

Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation

Mayo ClinicPhase 2Active
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
30/ 100
Competitive Position
95/ 100

Competitive context

15 Active assets in the Recurrent Diffuse Large B-Cell Lymphoma Associated With Chronic Inflammation cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Northwestern University
Phase 2/3BB
VINCRISTINE SULFATE
Northwestern University
Phase 2/3BB
Inno-206
Northwestern University
Phase 2/3BB
Cyclophosphamide
Mayo Clinic
Phase 2/3B
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Mayo Clinic
Phase 2/3B

View all 15 →

Same molecule, other indications

Maplirpacept is also rated in:

diffuse large B-cell lymphomaDormant
CCC
Indicative ·
51 / 100
View asset →
ALK-positive large B-cell lymphomaDormant
CC
Indicative ·
45 / 100
View asset →
B-cell non-Hodgkin lymphomaDormant
CC
Indicative ·
45 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →